BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc is a leading global biotechnology company headquartered in San Rafael, California, with locations in the United States, South America, Asia, and Europe. Established in 1997, BioMarin is engaged in the development and commercialisation of therapies for rare genetic diseases in children and adults, with its main focus on enzyme replacement therapies and various types of gene therapy. The firm has successfully brought to market various treatments for rare genetic diseases such as achondroplasia, phenylketonuria, morquio A syndrome, and CLN2 disease, with more products at various research stages in the firm’s pipeline. BioMarin owns and operates its own manufacturing facilities, allowing for a high degree of quality control and efficiency in its manufacturing process. These facilities include three current Good Manufacturing Practices (cGMP) plants in Novato, California, and Shanbally, Ireland. The firm has around 3,000 employees worldwide, and Forbes named BioMarin one of America’s Best Midsize Employers in 2019. The firm owns various subsidiary companies, including Prosensa, BioMarin Europe Ltd., Zacharon Pharmaceuticals Inc., Glyko Inc., Huxley Pharmaceuticals Inc., and LEAD Therapeutics Inc. The company is listed on the NASDAQ, where it trades under the ticker BMRN. Add BMRN stock to your eToro watchlist today to get real-time updates on Biomarin share price movements.